Transcend Capital Advisors LLC Buys 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Transcend Capital Advisors LLC boosted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 363,913 shares of the biopharmaceutical company's stock after buying an additional 37,059 shares during the period. Transcend Capital Advisors LLC owned approximately 0.12% of Amicus Therapeutics worth $3,428,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of FOLD. Creative Planning boosted its stake in Amicus Therapeutics by 79.6% in the 3rd quarter. Creative Planning now owns 52,855 shares of the biopharmaceutical company's stock worth $564,000 after purchasing an additional 23,433 shares during the period. Blue Trust Inc. boosted its position in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,831 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Amicus Therapeutics by 141.1% during the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock worth $21,765,000 after buying an additional 1,192,489 shares during the period. Legacy Capital Group California Inc. bought a new position in shares of Amicus Therapeutics during the third quarter worth about $206,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 1,884 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on FOLD. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Guggenheim boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Amicus Therapeutics Stock Down 2.5 %

FOLD traded down $0.23 during midday trading on Tuesday, reaching $9.11. 2,307,271 shares of the company were exchanged, compared to its average volume of 2,330,282. Amicus Therapeutics, Inc. has a one year low of $8.78 and a one year high of $14.02. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -50.61, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. The company's fifty day moving average price is $9.55 and its 200 day moving average price is $10.40. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.